GLP-1s vs. Older Weight-Loss Pills: Phentermine, Contrave, and Qsymia Compared

GLP-1s aren't the first FDA-approved weight-loss medications, and for some people an older, cheaper pill is a genuinely reasonable place to start or a fallback if a GLP-1 isn't accessible. Here's an honest, evidence-based comparison rather than a sales pitch for one class over another.

The older options, briefly

A handful of oral medications predate the GLP-1 era and remain FDA-approved for weight management: phentermine (a short-term-use appetite suppressant, often the cheapest option by far), phentermine-topiramate (brand name Qsymia, combining an appetite suppressant with an anticonvulsant that also reduces appetite), naltrexone-bupropion (brand name Contrave, combining an opioid antagonist with an antidepressant), and orlistat (brand name Xenical or over-the-counter Alli, which blocks fat absorption in the gut rather than acting on appetite centrally). All four have real trial evidence behind them and decades of real-world prescribing.

What the head-to-head evidence actually shows

The clearest recent answer comes from a 2024 network meta-analysis published in The Lancet, which pooled randomized controlled trial data across essentially every approved obesity pharmacotherapy — GLP-1s included — to rank them by effectiveness¹. The consistent finding: GLP-1 receptor agonists and the dual GIP/GLP-1 agonist tirzepatide produced substantially greater average weight loss than any of the older oral options in that analysis¹. An earlier 2016 systematic review and meta-analysis in JAMA, covering the pre-GLP-1 generation of obesity drugs, had already established the ballpark for the older options: average weight loss in the roughly 3–9% range over placebo depending on the drug, well below what the pivotal GLP-1 trials would later report² — semaglutide's roughly 15% and tirzepatide's roughly 21% average loss at their top doses³⁴.

Why the gap is that large

The older pills largely work through a single lever — suppressing appetite centrally, or (for orlistat) blocking a fraction of dietary fat absorption. GLP-1s work through a broader mechanism: slowing gastric emptying, acting on appetite and satiety centers in the brain, and, for tirzepatide, activating a second gut-hormone receptor (GIP) on top of GLP-1¹. More mechanisms acting together plausibly explains why the average results are so much larger, though "larger average effect" doesn't mean every individual does better on a GLP-1 than they would on an older option — individual response varies with any of these drugs.

Where the older options still make sense

Cost is the biggest one — generic phentermine can run a small fraction of even the cheapest compounded GLP-1, which matters if budget is the binding constraint; see our real pricing breakdowns in semaglutide cost without insurance. Access is another: some insurance plans exclude GLP-1s for weight loss entirely but will cover an older, cheaper drug, or a prescriber may start with a lower-intensity option before escalating — see does insurance cover GLP-1 weight-loss drugs. Tolerability profile differs too: GLP-1 GI side effects (nausea, vomiting) don't suit everyone, and some people tolerate an older appetite suppressant better, though those come with their own side-effect profiles (elevated heart rate and blood pressure with phentermine-based options, for instance) that a prescriber needs to weigh against your health history. And needle aversion is real — all four older options are oral, while brand-name GLP-1s for weight loss are injectable (oral semaglutide exists but at a lower approved dose than the injectable weight-management version) — see injections vs. oral GLP-1 for that trade-off.

The honest bottom line

If maximum average weight loss backed by the largest trials is your priority and you can access and afford a GLP-1, the evidence favors it clearly over the older oral options¹². If cost, access, or tolerability push you toward an older medication, that's a legitimate, evidence-based choice too — these aren't fringe drugs, they're FDA-approved options with real trial data, just a smaller average effect than the newer class. Either way, this is a conversation to have with a prescriber who will actually walk through your options rather than default to whichever drug their business model is built around — see how to choose a GLP-1 provider for what that oversight should look like, or take the quiz to see which providers fit your priorities.